Intrust Bank’s Corcept Therapeutics CORT Stock Holding History

Intrust Bank’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-10,200	Closed	-$120K	–	360
2019 Q1	$120K	Sell	10,200 -13,577	-57%	-$169K	0.03%	372
2018 Q4	$318K	Buy	+23,777	New	+$314K	0.09%	253
2018 Q3	–	Sell	-15,286	Closed	-$240K	–	369
2018 Q2	$240K	Buy	15,286 +3,704	+32%	+$64.4K	0.07%	322
2018 Q1	$191K	Buy	+11,582	New	+$215K	0.06%	352

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Intrust Bank's CORT Position: Q2 2019 in Review

Intrust Bank sold out of Corcept Therapeutics (CORT) in Q2 2019, closing a stake of 10,200 shares — an estimated $120K sold.

Intrust Bank first reported a position in CORT in Q1 2018 and held it in 4 quarters. The position peaked at $318K in Q4 2018. 183 funds tracked by Wall St. Rank hold CORT as of Q2 2019.

Intrust Bank reported no remaining Corcept Therapeutics position as of Q2 2019 after selling out during the quarter.
Intrust Bank sold 10,200 Corcept Therapeutics shares in Q2 2019, an estimated $120K.
Intrust Bank first reported a position in Corcept Therapeutics in Q1 2018 and held it in 4 quarters.
Intrust Bank's Corcept Therapeutics position peaked at $318K in Q4 2018.
183 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2019.

Based on Intrust Bank's 13F filing for Q2 2019, filed 12 Aug 2019.